ENDRA Life Sciences Inc. (NDRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
NDRA Stock Price Chart Interactive Chart >
NDRA Price/Volume Stats
|Current price||$0.23||52-week high||$2.44|
|Prev. close||$0.24||52-week low||$0.18|
|Day high||$0.25||Avg. volume||1,882,812|
|50-day MA||$0.29||Dividend yield||N/A|
|200-day MA||$0.90||Market Cap||10.09M|
ENDRA Life Sciences Inc. (NDRA) Company Bio
ENDRA Life Sciences Inc. operates as a biotechnology company. The Company develops a medical imaging technology based on the thermoacoustic effect that improves the sensitivity and specificity of clinical ultrasound. ENDRA Life Sciences serves customers worldwide.
Most Popular Stories View All
NDRA Latest News Stream
|Loading, please wait...|
NDRA Latest Social Stream
View Full NDRA Social Stream
Latest NDRA News From Around the Web
Below are the latest news stories about ENDRA Life Sciences Inc that investors may wish to consider to help them evaluate NDRA as an investment opportunity.
The Stock Day Podcast Hosted ENDRA Life Sciences Inc. to Discuss the Potential of its Thermo Acoustic Enhanced UltraSound (TAEUS(R))
Phoenix, Arizona--(Newsfile Corp. - February 15, 2022) - The Stock Day Podcast welcomed ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("the Company"), the pioneer of Thermo; Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. CEO of the Company, Francois Michelon, joined Stock Day host Everett Jolly.Jolly began the interview by asking about the Company's decision to ...
ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Portfolio with Issuance of 6th and 7th European Patents
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office (EPO) has issued two new patents to ENDRA, European Patent No. 3668382 (the ‘382 patent) titled “Method and System for Estimating Fractional Fat Content of an Object” and European Patent No. 3661416 (the ‘416 patent) titled “Method for Estimating Fractional Fat Content of an Object.” The ‘382 patent protects ENDRA''s meth
Good morning, trader!
ENDRA Life Sciences Inc (NASDAQ: NDRA ) plans to voluntarily withdraw its 510(k) application , currently under FDA review for its TAEUS System. Instead, the Company will subsequently submit a De Novo application. TAEUS is initially focused on measuring fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Full story available on Benzinga.com
ANN ARBOR, Mich., February 09, 2022--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today it will build on the content of its completed 510(k) application and pursue the De Novo pathway for its TAEUS System, which is intended to characterize fatty liver tissue as a means to non-invasively assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD).
NDRA Price Returns